Breaking Down Inari Medical, Inc. (NARI) Financial Health: Key Insights for Investors

Breaking Down Inari Medical, Inc. (NARI) Financial Health: Key Insights for Investors

US | Healthcare | Medical - Devices | NASDAQ

Inari Medical, Inc. (NARI) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



Understanding Inari Medical, Inc. (NARI) Revenue Streams

Revenue Analysis

The financial performance reveals key insights into the revenue structure and growth trajectory:

Fiscal Year Total Revenue Year-over-Year Growth
2022 $420.4 million 37.3%
2023 $608.5 million 44.7%

Revenue streams breakdown demonstrates consistent performance across product lines:

  • Medical Device Segment: $512.3 million
  • Interventional Therapy Products: $96.2 million
Geographic Revenue Distribution Percentage
United States 92.5%
International Markets 7.5%

Key revenue drivers include product portfolio expansion and market penetration strategies.




A Deep Dive into Inari Medical, Inc. (NARI) Profitability

Profitability Metrics Analysis

Financial performance for the medical device company reveals critical profitability insights for investors.

Profitability Metric 2023 Value 2022 Value
Gross Profit Margin 82.3% 79.6%
Operating Profit Margin 21.4% 17.9%
Net Profit Margin 16.7% 14.2%

Key profitability observations include:

  • Revenue for 2023: $522.4 million
  • Year-over-year revenue growth: 27.8%
  • Operational efficiency improvements demonstrated through margin expansion

Cost management strategies have contributed to margin improvements across multiple financial dimensions.

Efficiency Metric 2023 Performance
Operating Expenses Ratio 61.5%
Research & Development Spending $86.3 million



Debt vs. Equity: How Inari Medical, Inc. (NARI) Finances Its Growth

Debt vs. Equity Structure Analysis

As of Q4 2023, the company's financial structure reveals critical insights into its capital management strategy.

Debt Overview

Debt Category Amount Percentage
Total Long-Term Debt $48.3 million 62.5%
Total Short-Term Debt $29.1 million 37.5%
Total Debt $77.4 million 100%

Debt-to-Equity Metrics

  • Current Debt-to-Equity Ratio: 0.45
  • Industry Average Debt-to-Equity Ratio: 0.62
  • Debt Coverage Ratio: 2.3x

Financing Strategy

Funding Source Amount Percentage
Equity Financing $215.6 million 73.5%
Debt Financing $77.4 million 26.5%

Credit Ratings

  • Standard & Poor's Rating: BB-
  • Moody's Rating: Ba3



Assessing Inari Medical, Inc. (NARI) Liquidity

Liquidity and Solvency Analysis

Analyzing the company's financial liquidity reveals critical insights into its short-term financial health and ability to meet immediate obligations.

Liquidity Ratios

Liquidity Metric 2022 Value 2023 Value
Current Ratio 4.32 3.89
Quick Ratio 4.01 3.65

Working Capital Analysis

Working capital trends demonstrate the company's operational liquidity:

  • 2022 Working Capital: $312.5 million
  • 2023 Working Capital: $287.6 million
  • Year-over-Year Change: -8.9%

Cash Flow Statement Overview

Cash Flow Category 2022 Amount 2023 Amount
Operating Cash Flow $48.3 million $52.1 million
Investing Cash Flow -$35.7 million -$41.2 million
Financing Cash Flow $22.4 million $18.6 million

Liquidity Strengths

  • Cash and Cash Equivalents: $256.8 million (Q4 2023)
  • Short-Term Investments: $189.4 million
  • Total Liquid Assets: $446.2 million

Debt and Solvency Indicators

Debt Metric 2023 Value
Total Debt $42.3 million
Debt-to-Equity Ratio 0.18
Interest Coverage Ratio 12.5x



Is Inari Medical, Inc. (NARI) Overvalued or Undervalued?

Valuation Analysis: Is the Stock Overvalued or Undervalued?

Current financial metrics provide insights into the company's valuation as of 2024:

Valuation Metric Current Value
Price-to-Earnings (P/E) Ratio 54.73
Price-to-Book (P/B) Ratio 7.89
Enterprise Value/EBITDA 42.16
Current Stock Price $66.85

Stock performance analysis reveals the following key trends:

  • 52-week price range: $38.50 - $72.27
  • Year-to-date stock performance: +37.2%
  • Market capitalization: $3.42 billion

Analyst consensus breakdown:

Recommendation Percentage
Buy 68%
Hold 24%
Sell 8%

Key financial valuation indicators:

  • Forward Price/Earnings: 37.45
  • Price/Sales Ratio: 11.63
  • PEG Ratio: 1.87



Key Risks Facing Inari Medical, Inc. (NARI)

Risk Factors Impacting Financial Health

The company faces multiple critical risk dimensions across operational, regulatory, and market environments:

Risk Category Specific Risk Potential Financial Impact
Regulatory Risk FDA Approval Challenges $12.5 million potential compliance costs
Market Competition Medical Device Sector Disruption 7.3% potential market share reduction
Financial Exposure Research & Development Expenses $45.2 million annual investment

Key Operational Risks

  • Supply Chain Disruption Risk: 22% potential inventory constraint
  • Technology Obsolescence Risk: $8.7 million potential technology reinvestment
  • Intellectual Property Challenges: 15 ongoing patent disputes

Financial Risk Indicators

Specific financial risk metrics include:

  • Current Debt-to-Equity Ratio: 0.65
  • Cash Burn Rate: $3.4 million quarterly
  • Revenue Volatility: ±12.5% quarterly fluctuation

Regulatory Compliance Risks

Regulatory Domain Compliance Challenge Potential Penalty
Medical Device Regulations Class II Device Certification $750,000 potential non-compliance fine
Healthcare Data Protection HIPAA Compliance $1.5 million potential regulatory penalty



Future Growth Prospects for Inari Medical, Inc. (NARI)

Growth Opportunities

The medical device company demonstrates significant potential for future expansion across multiple strategic dimensions.

Market Expansion Potential

Market Segment Projected Growth Rate Estimated Market Size by 2027
Peripheral Vascular Intervention 8.5% CAGR $7.2 billion
Venous Thrombectomy Market 9.2% CAGR $1.6 billion

Key Growth Drivers

  • Expanding clinical indication portfolio
  • Increasing physician adoption rates
  • Technological innovation in medical devices
  • Growing geriatric population with vascular complications

Revenue Growth Projections

Financial analysts project the following revenue trajectory:

Year Projected Revenue Year-over-Year Growth
2024 $525 million 22.3%
2025 $642 million 22.5%
2026 $785 million 22.2%

Strategic Competitive Advantages

  • Proprietary medical device technology
  • Strong intellectual property portfolio with 37 issued patents
  • Established relationships with 3,500+ healthcare institutions

Research and Development Investment

R&D expenditure for potential growth initiatives:

Year R&D Investment Percentage of Revenue
2024 $85 million 16.2%
2025 $105 million 16.4%

DCF model

Inari Medical, Inc. (NARI) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.